ALLO Stock — Allogene Therapeutics, Inc.

Up next

Next earnings call

Mar 11, 2027 Est · unconfirmed · in 17 wks

Q2 2026 earnings call transcript

call held Aug 12, 2026

Play latest call

Latest documents

what the company just published, in one sentence each

2026

Nov 6

Quarterly report 10-Q FY2026 Q3, ended Sep 30

ALPHA3 interim data favored cema-cel over observation

Allogene Therapeutics reported ALPHA3 interim results showing MRD negativity in 58.3% (7/12) of cema-cel patients versus 16.7% (2/12) under observation, with no treatment-related serious adverse events reported in the cema-cel arm.

Revenue $0 Net loss $50.37M Diluted EPS -$0.15

Read from the MD&A section

4 source passages

Unless the context requires otherwise, references to the “Company”, “Allogene,” “we,” “us” and “our” refer to Allogene Therapeutics, Inc. On April 13, 2026, we announced results from the planned interim futility analysis of the first 24 randomized patients to the two ongoing arms in ALPHA3. At the protocol-defined data cutoff, which was triggered when the 24th patient completed Day 45 MRD assessment, MRD negativity was observed in 58.3% (7/12) of patients in the cema-cel arm compared with 16.7% (2/12) of patients in the observation arm, and at the Day 45 post-randomization MRD assessment, ctDNA levels decreased from baseline by a median of 97.7% in the cema-cel arm compared with a median increase of 26.6% in the observation arm. In the cema-cel arm, no treatment-related serious adverse events, cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, graft-versus-host disease or treatment-related hospitalizations were reported, and ten of the twelve treated patients were managed in the outpatient setting post-infusion. Open the document at this passage

Nov 5

Current report 8-K

Clinical trial update and cash runway

Allogene Therapeutics reported $388.9 million in cash, cash equivalents and investments as of September 30, 2026. It anticipates a clinical update in mid-2027, enrollment completion by year-end 2027, and a cash runway into 2029.

Financial results

4 source passages

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today provided corporate updates and reported financial results for the quarter ended September 30, 2026. The Company had $388.9 million in cash, cash equivalents, and investments as of September 30, 2026. The Company continues to anticipate its next clinical update in mid-2027, with trial enrollment expected to be completed by year-end 2027. Based on its cash, cash equivalents, and investments as of September 30, 2026, the Company continues to project its cash runway into 2029. Open the document at this passage

Sep 9

Investor event

Citi Biopharma Back to School Conference AI summary on its way

Sep 2

Current report 8-K Events of Aug 31

Director or officer change, or executive pay AI summary on its way

Aug 12

Earnings call

Q2 2026 earnings call AI summary on its way

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

View all 125 metrics

Revenue (TTM)

$4.64M

Trailing 12 months

Net income (TTM)

−$174.46M

Trailing 12 months

Revenue growth YoY

-100.0%

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-37.4%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$29.27M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+55.9%

Year over year · more shares

Price change (1Y)

-30.1%

Trailing year

Short interest

14.8%

Latest settlement · 6.2 days to cover

View all 125 metrics

Quarterly results

Revenue Net income Net loss

▼100% $0 −$66.29M '24 Q3 ▼100% $0 −$59.94M '24 Q4* ▼100% $0 −$59.73M '25 Q1 · $0 −$50.94M '25 Q2 · $0 −$41.40M '25 Q3 · $0 −$38.81M '25 Q4* · $4.64M −$42.68M '26 Q2 LATEST · $0 −$50.37M '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

AI Brief

Q2 FY26 earnings call · Aug 12, 2026

Q2 FY26

TL;DR. Allogene's Q2 2026 was highlighted by FDA RMAT and Fast Track designations for cema-cel in 1L LBCL consolidation, accelerated ALPHA3 site activation to ~100 by year-end (six months ahead of plan), and brisk ALLO-329 enrollment with a Q4 2026 clinical update planned; cash runway extends into 2029, though the company posted a $42.7M net loss.

Bullish

+ FDA granted RMAT and Fast Track designations for cema-cel as 1L consolidation therapy in July 2026 following review of the interim futility analysis.
+ ALPHA3 interim futility analysis showed a 41.6% absolute MRD clearance advantage for cema-cel vs observation with a favorable outpatient safety profile and no treatment-related serious adverse events.
+ ALPHA3 site activation target accelerated by six months; ~100 sites now expected active by year-end 2026 versus prior 80-site goal.
+ ALLO-329 RESOLUTION trial enrollment is brisk across dose escalation and lymphodepletion cohorts, with a clinical and translational update on track for Q4 2026.
+ Cash runway projected into 2029 supported by $423.6M in cash, cash equivalents and investments as of June 30, 2026.

Bearish

− Company reported a Q2 2026 net loss of $42.7M ($0.13 per share).
− ALLO-316 TRAVERSE program has faced real safety challenges despite notable 31% confirmed ORR in CD70-high RCC.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Strong Sell

SellHoldBuy

Technical Strong Sell Momentum Very Weak Sentiment Bullish Fundamentals Weak Quant / Vol Very High

Market backdrop VIX 19.3 · elevated Equity put/call 0.63

Technical

price trend

Strong Sell

50 / 200-day cross No cross

Price vs 200-day avg −57%

below

Price vs 50-day avg −41%

below

RSI (14) 23

oversold

MACD trend Negative

52-week position 1%

near low

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −36%

trailing

6-month return −60%

trailing

YTD return −39%

this year

Relative strength −61%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $1 › 200d $2 — 200d above 50d

Institutional flow Accumulating

165 of 210 funds reported for Sep 30 · net +8.7M sh shares · +18 new

Insider flow Distributing

Net -$111.7K over 90 days · 100% sells

Short interest Falling

14.80% of shares out · ▼ -4.0% MoM · 6.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

210 holders — near 3-yr high, broad support

Squeeze score 62

elevated · 0–100

Fundamentals

Weak

Revenue growth −100%

Y/Y

EPS growth +34%

Y/Y

Free cash flow $-149.6M

Quant / Vol

risk profile

Very High

Volatility 84%

annualized · 1-yr

Max drawdown −73%

past year

ATR 11.5%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the 8-K filed Aug 12, 2026

Operating expense · 2026 $165M

GAAP Operating Expenses · 2026 GAAP Raised $225M

May 13, 2026 $210M – $225M Aug 12, 2026 $225M

Previous outlook earlier release · from the Earnings Call filed May 13, 2026

Still-open targets the latest release did not restate under the same label.

Operating cash expense · 2026 $150M – $165M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell

4 · 3 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−57% Bearish

Price vs 50-day avg

−41% Bearish

RSI (14)

23 Neutral

MACD trend

Negative Bearish

52-week position

1% Bearish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $1 › 200d $2 — 200d above 50d

Institutional flow Accumulating

165 of 210 funds reported for Sep 30 · net +8.7M sh shares · +18 new

Insider flow Distributing

Net -$111.7K over 90 days · 100% sells

Short interest Falling

14.80% of shares out · ▼ -4.0% MoM · 6.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

210 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $1 Now $1 · 1% Range high $3

vs 200-day avg -57% vs 50-day avg -41%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
All other development costs	3.07M	Three Months Ended September 30, 2026 filing	—
Cema-cel	13.95M	Three Months Ended September 30, 2026 filing	—
Clinical trial milestones recorded as research and development expenses	$1.6M	three months ended September 30, 2026 filing	—
Collaboration costs recorded as research and development expenses	$0.2M	three months ended September 30, 2026 filing	—
Facilities & IT-related spend	6.99M	Three Months Ended September 30, 2026 filing	—
Other operating expenses	9.65M	Three Months Ended September 30, 2026 filing	—
Payroll	15.41M	Three Months Ended September 30, 2026 filing	—
Supporting external spend	5.73M	Three Months Ended September 30, 2026 filing	—
Workforce Reduction	28%	the second quarter of 2025 filing	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
ALLO Allogene Therapeutics, Inc. this stock	$290.58M	-38.8%	-100.0%	—	14.8%
VRTX Vertex Pharmaceuticals Inc	$136.56B	+18.8%	+46.2%	34.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$98.84B	+23.8%	+20.8%	21.1	2.1%
MRNA Moderna, Inc.	$90.38B	+657.4%	+4.3%	—	8.2%
CSLLY Csl Ltd	$66.05B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

205

% held: 92.9%
Reported: 165 of 210
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

175

View

Short & Settlement

Short Interest Falling

Shares short

51.3M

Days to cover: 6.2d
Change: -2.1M sh

View

Short Volume

Short vol %

33%

As of: Nov 13, 2026

Short Total

View

Fails to Deliver

FTD shares

18.5K

Value: $26.5K
As of: Oct 8, 2026

View

Off-Exchange

Off-exchange %

62.5%

Week of: Oct 5, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$111.7K

Buyers / Sellers: 0 / 2

Buyers Sellers

View

Financials

Revenue (FY)

$0

Net income (FY): $-190.9M
EPS diluted: $-0.87

View

Filings

SEC Filings

Latest

10-Q

Filed: Nov 6, 2026
This year: 24

Allogene Therapeutics reported ALPHA3 interim results showing MRD negativity in 58.3% (7/12) of cema-cel patients versus 16.7% (2/12) under observation, with no treatment-related serious adverse events reported in the cema-cel arm.

View

Proposed Sales

Value

$48.7K

Shares: 36.3K
Filed: Oct 21, 2026

View

Earnings & Events

Webcasts Upcoming

Next webcast

Nov 16, 2026

Last webcast: Nov 5, 2026

View

Investor Relations

	5D	20D	120D	MTD	YTD
ALLO	-19.4%	-36.0%	-60.4%	-28.9%	-38.8%
SPY	+2.6%	-1.2%	+0.5%	-0.2%	+10.6%
vs SPY	-22.0%	-34.8%	-60.9%	-28.7%	-49.4%

ALLO · Allogene Therapeutics, Inc.

Price & Indicators

Up next

Latest documents

Metrics snapshot

Quarterly results

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance